A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

BACKGROUND: Myelotoxicity during initial cycles of chemotherapy for Hodgkin lymphoma is associated with better outcome, supporting the concept of individualised dosing based on pharmacodynamic end points to optimise results. This study was performed to identify the maximum tolerated dose (MTD) of do...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibb, A, Greystoke, A, Ranson, M, Linton, K, Neeson, S, Hampson, G, Illidge, T, Smith, E, Dive, C, Pettitt, A, Lister, A, Johnson, P, Radford, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833204/
https://www.ncbi.nlm.nih.gov/pubmed/24136151
http://dx.doi.org/10.1038/bjc.2013.605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833204/
https://www.ncbi.nlm.nih.gov/pubmed/24136151
http://dx.doi.org/10.1038/bjc.2013.605

Ejemplares similares